One study has shown that systemic inhibition of type I interferon secretion by Axl can lead to the expansion of tumor associated TCF1+PD-1+CD8 T cells and restore the therapeutic response of lung cancer to ICIs (38). The gene discussed is CD8A; the disease is lung carcinoma.